CAPTRUST Financial Advisors
CRSP icon

CAPTRUST Financial Advisors’s CRISPR Therapeutics CRSP Stock Holding History

CAPTRUST Financial Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,000
Closed -$91 – 2699
2023
Q3 		$91 Buy
+2,000
New +$103K ﹤0.01% 2603

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

CAPTRUST Financial Advisors's CRSP Position: Q2 2026 in Review

CAPTRUST Financial Advisors increased its CRISPR Therapeutics (CRSP) stake by 2.6% in Q2 2026, buying an estimated $33.6K and bringing the position to 25,262 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #1557.

CAPTRUST Financial Advisors first reported a position in CRSP in Q2 2018 and has held it in 31 quarters since. The position peaked at $3.44M in Q2 2021. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • CAPTRUST Financial Advisors held 25,262 shares of CRISPR Therapeutics worth $1.38M as of Q2 2026.
  • CAPTRUST Financial Advisors bought 637 CRISPR Therapeutics shares in Q2 2026, an estimated $33.6K.
  • CRISPR Therapeutics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #1557 holding.
  • CAPTRUST Financial Advisors first reported a position in CRISPR Therapeutics in Q2 2018 and has held it in 31 quarters since.
  • CAPTRUST Financial Advisors's CRISPR Therapeutics position peaked at $3.44M in Q2 2021.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.